Back to top

Image: Bigstock

LabCorp (LH) Beats on Q3 Earnings & Revenue Estimates

Read MoreHide Full Article

Laboratory Corp. of America Holdings (LH - Free Report) is a leading independent clinical laboratory, whose offerings include a broad range of routine tests (including blood chemistry analysis, urinalyses, blood cell count, thyroid test, Pap tests and HIV tests) as well as specialty testing operations or esoteric testing.

Currently, LabCorp has a Zacks Rank #2 (Buy) but that could change following its third quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:

Earnings: The Zacks Consensus Estimate is pegged at $2.38 per share over the last 30 days. LabCorp’s adjusted earnings per share of $2.46 is also up 9.3% on year-over-year basis.

Sales: LabCorp posted sales of $2.65 billion, which has beaten the Zacks Consensus Estimate for sales of $2.56 billion. The figure is also up 9.9% on year-over-year basis.

Key Stats: Revenues from LabCorp Diagnostics segment increased 9.9% year over year to $1.84 billion in the third quarter, with total volume growth of 7.3%. Revenues from Covance Drug Development segment increased 8.6% to $761.1 million, owing to the acquisition of Chiltern, as well as organic growth and the benefit from foreign currency translation.

Major Factors: Management seemed to be upbeat about LabCorp’s impressive third quarter results. Per management, the Diagnostics business had witnessed strong organic and total volume growth despite the adverse impact from hurricanes. Also, the Drug development business witnessed solid growth on the back of increased net orders and improving net book-to-bill. The company has also increased its 2017 guidance.

Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session

Check back later for our full write up on this LabCorp earnings report later!

Zacks' Hidden Trades

While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?

Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.

Click here for Zacks' secret trade>>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Labcorp (LH) - free report >>

Published in